Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News

Novel imaging approach may improve treatment for spinal cord injuries

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

Tirzepatide may only temporarily suppress brain 'food noise' activity

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

New tool predicts graft failure after kidney transplant

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

Supercomputer simulation is changing how we study the brain

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

AI tool creates digital twins of patients to predict their future health

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

How are patients using health care chatbots? Study finds some 'eye-openers'

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

News All Time

At some doctors' offices, AI is listening in the exam room

Bracken Babula starts patient visits these days by closing the exam room door and asking if they mind him recording their conversation. He hits a button on his mobile phone, checks that it is recording, and sits back in his ...

Software optimizes brain simulations, enabling them to complete complex cognitive tasks

A new software enables brain simulations which both imitate the processes in the brain in detail and can solve challenging cognitive tasks. The program was developed by a research team at the Cluster of Excellence "Machine ...

GLP-1 and health: Beyond weight loss in the Ozempic era

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people ...

When life imitates art: Google searches for anxiety drug spike during run of The White Lotus TV show

In season three of the hit television series "The White Lotus," the character Victoria Ratliff takes the prescription anti-anxiety medication lorazepam to help with her social anxiety and inability to sleep. Her casual usage ...

Digital access improves convenience, but cannot fully replace physical services

A research team from the Urban and Transportation Systems Laboratory, Department of Architecture and Civil Engineering, Toyohashi University of Technology, has developed an innovative evaluation framework that quantitatively ...

Deep learning system could transform skin cancer detection with near-perfect accuracy

Melanoma remains one of the hardest skin cancers to diagnose because it often mimics harmless moles or lesions. While most artificial intelligence (AI) tools rely on dermoscopic images alone, they often overlook crucial patient ...

How the brain learns and applies rules: Sequential neuronal dynamics in the prefrontal cortex

Understanding how the brain learns and applies rules is the key to unraveling the neural basis of flexible behavior. A new study from the University of Toyama, Japan, reveals that our ability to follow procedural rules is ...

Computational deep dive reveals hidden cancer drug targets and repurposing opportunities

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

Wireless incubator enables remote monitoring of premature infants from 30 meters away

A wireless, portable incubator that could transform care for premature infants is reported in the International Journal of Medical Engineering and Informatics. It offers remote monitoring and automated environmental control ...

Speeding the detection of three serious regional fungal infections

Certain serious fungal infections occur in regions of the United States with specific environments and are often tied to soil exposure. These infections can affect both healthy and immunocompromised people, but proper diagnosis ...

Molecular test could allow for more accurate Lyme disease diagnosis

Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods.

Kidney organoids uncover Hippo signaling pathway as a therapeutic target for nephronophthisis

Using human-induced pluripotent stem cell-derived kidney organoids, researchers from Science Tokyo uncovered how abnormal Hippo signaling drives fibrosis in nephronophthisis, a genetic kidney disorder caused by NPHP1 deficiency.

FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).

FDA approves Caplyta for major depressive disorder in adults

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults.

Family history key to predicting antidepressant response

A new study from Queen Mary University of London shows that a family's experience with certain medicines could help doctors predict how future generations will respond to the same drugs.

Artificial intelligence, wellness apps alone cannot solve mental health crisis, warn experts

Emotional support is an increasingly common reason people turn to generative artificial intelligence chatbots and wellness applications, but these tools currently lack the scientific evidence and the necessary regulations ...

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

Researchers discover cellular 'doorway' exploited by cancer-causing virus

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Routine breast cancer screening can bring better outcomes for patients

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

Drop in credit score after cancer diagnosis linked to increased mortality

Recommended Articles For You

Vaccines that can help prevent cancer 

A New Perspective on Spherocytosis: Uncovering Innovative Treatments 

Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care 

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survey shows cancer anxiety has impact well beyond the individual diagnosed

2.

Cancer care crowdfunding increasingly common, but rarely successful

3.

Novel radiotracer identifies biomarker for triple-negative breast cancer

4.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

5.

June 20, 2023, Health Bulletin No. 12.

1.

Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights

2.

Navigating the Complexities of Melanoma Staging: A Comprehensive Guide

3.

Navigating the Stages of Thyroid Cancer: A Guide for Patients

4.

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology

5.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

2.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

5.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot